MCMCB Pro
C1830

C1830Powered bone marrow biopsy needle

HCPCSActiveBETOS D1A

C1830 is a HCPCS Level II code for powered bone marrow biopsy needle. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.

Medicare coverage: Special coverage instructions apply

There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q3-Jul. This states Medicare’s position on the code, not on your particular claim.

Medically Unlikely Edits — units per day

The most units of C1830 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.

practitioner
2 units
MAI 3 — Date of Service Edit: Clinical · Nature of Service/Procedure
outpatient
2 units
MAI 3 — Date of Service Edit: Clinical · Nature of Service/Procedure

The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute — no documentation overrides it. CMS MUE 2026Q3.

The CMS record for C1830

Long descriptor
Powered bone marrow biopsy needle

The official wording. This is what the code means.

Short descriptor
Power bone marrow bx needle

CMS's 28-character form, which is what shows up on a remittance advice.

Added
October 1, 2011

When CMS introduced the code.

BETOS
D1A

Berenson-Eggers Type of Service — CMS's own analytic grouping.

Pricing indicator
53 — Other

Statute.

Codes adjacent to C1830

HCPCS has no hierarchy — related items simply sit next to each other in the numbering. If C1830 is not quite right, the correct code is very often within a few positions of it.

  • C1820Generator, neurostimulator (implantable), with rechargeable battery and charging system
  • C1821Interspinous process distraction device (implantable)
  • C1822Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system
  • C1823Generator, neurostimulator (implantable), non-rechargeable, with transvenous sensing and stimulation leads
  • C1824Generator, cardiac contractility modulation (implantable)
  • C1825Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)
  • C1826Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system
  • C1827Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller
  • C1831Interbody cage, anterior, lateral or posterior, personalized (implantable)
  • C1832Autograft suspension, including cell processing and application, and all system components
  • C1833Monitor, cardiac, including intracardiac lead and all system components (implantable)
  • C1834Pressure sensor system, includes all components (e.g., introducer, sensor), intramuscular (implantable), excludes mobile (wireless) software applicationterminated
  • C1839Iris prosthesis
  • C1840Lens, intraocular (telescopic)
  • C1841Retinal prosthesis, includes all internal and external componentsterminated
  • C1842Retinal prosthesis, includes all internal and external components; add-on to c1841terminated

Questions about C1830

What is HCPCS code C1830?

C1830 is a HCPCS Level II code for powered bone marrow biopsy needle. It sits in the Outpatient Prospective Payment System section.

Does Medicare cover C1830?

The CMS HCPCS file marks C1830 as "Special coverage instructions apply". There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.

HCPCS Level II2026Q3-Jul· effective July 1, 2026